

Sharo

Digitally signed by

Sharon E. Kennedy

DN: cn=Sharon E.

Kennedy, o=USPTO

ou=1615,

email=sharon.e.kennedy@uspto.gov

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**KENNEDY, TONY DISCLOSURE
STATEMENT BY APPLICANT**

Date: 2007.09.24

17:21:24 -04'00'

(Use as many sheets as necessary)

Sheet

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/SK/		US- 4,806,595	2-21-89	Noishiki et al.	all
		US- 5,037,664	3-6-91	Kyogoku et al.	all
		US- 5,085,629	2-4-92	Goldberg et al.	all
		US- 5,170,446	12-14-93	Kyogoku et al.	all
		US- 5,322,1935	6-21-94	Smith	all
		US- 5,464,450	11-7-95	Buseomi et al.	all
		US- 5,516,781	5-14-96	Morris et al.	all
		US- 5,733,327	3-31-98	Igaki et al.	all
		US- 5,780,052	7-14-98	Khaw et al.	col. 1-22
		US- 5,929,038	7-27-99	chang	all
		US- 6,045,568	4-4-00	Igaki et al.	all
		US- 6,080,177	6-27-00	Igaki et al.	all
		US- 6,103,255	8-15-00	Levene et al.	all
		US- 6,160,084	12-12-00	Langer et al.	all
		US- 6,162,826	12-19-00	Muan et al.	all
		US- 6,200,335	3-13-01	Igaki	all
		US- 6,206,931	3-27-01	Cook et al.	all
		US- 6,262,083	7-17-01	Moen et al.	all
/SK/					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner Signature

/Sharon Kennedy/

Date Considered

09/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

5

Application Number	
Filing Date	
First Named Inventor	Hsing-Wen Sung
Art Unit	
Examiner Name	

Attorney Docket Number

S & T - 134

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/SK/		US- 6,264,992	7-24-01	Voytik-Harbin et al.	all
		US- 6,388,043	5-14-02	Langer et al.	all
		US- 6,395,300	5-28-02	Straub et al.	all
		US- 6,423,682	7-23-02	Ballinger et al.	col. 1-4
		US- 6,436,170	8-20-02	Tang et al.	col. 1-6
		US- 6,451,764	9-17-02	Lee et al.	col. 1-6
		US- 6,475,984	11-5-02	Papkoff	col. 1-4
		US- 6,476,211	11-5-02	Ford et al.	col. 1-8
		US- 6,485,920	11-26-02	Ballinger et al.	col. 1-6
		US- 6,544,544	4-8-03	Hunter et al.	claims
		US- 6,608,040	8-19-03	Lin et al.	all
		US- 6,624,138	9-23-03	Sung et al.	all
		US- 6,632,242	10-14-03	Igaki	all
		US-			
↓		US-patent application 2003/0055198	3-20-03	Langer et al.	all
/SK/		US-patent application 2004/10015187	1-22-04	Lendlein et al.	all
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner Signature

/Sharon Kennedy/

Date Considered

09/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
				<i>Application Number</i>	
				<i>Filing Date</i>	
				<i>First Named Inventor</i>	Hsing - Wen Sung
				<i>Art Unit</i>	
				<i>Examiner Name</i>	
Sheet	3	of	5	Attorney Docket Number	S&T- 134

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/SK/	1.	<i>RADAR DS, "High-density Lipoproteins as an emerging therapeutic target for atherosclerosis", JAMA 2003; 290(17) : 2322-2324</i>			
	2.	<i>NISSEN SE et al., "Effect of Recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes", JAMA 2003; 290(17) : 2292-2300</i>			
	3.	<i>NAGHAVI M et al., "From vulnerable plaque to vulnerable patient -part I", Circulation 2003; 108 : 1664-1672</i>			
	4.	<i>NAGHAVI M et al., "From vulnerable plaque to vulnerable patient - part II", Circulation 2003; 108 : 1772-1778</i>			
	5.	<i>SUNG HW et al., "Feasibility study of a natural crosslinking reagent for biological tissue fixation", J Biomed Mater Res 1998; 42: 560-567</i>			
	6.	<i>HUANG LL et al., "Biocompatibility study of a biological tissue fixed with a naturally occurring crosslinking reagent", J Biomed Mater Res 1998; 42: 568-576</i>			
	7.	<i>SUNG HW et al., "In vitro evaluation of cytotoxicity of a naturally occurring cross-linking reagent for biological tissue fixation", J Biomater Sci Polymer Edn 1999; 10(1) : 63-78</i>			
	8.	<i>SUNG HW et al., "A naturally occurring reagent for biological tissue fixation" in New Biomedical Materials, edited by Haris PI and Chapman D, pages 182-191 (1998), published by IOS Press</i>			
	9.	<i>SUNG HW et al., "Crosslinking characteristics and mechanical properties of a bovine pericardium fixed with a naturally occurring crosslinking agent", J Biomed Mater Res 1998; 42 : 16-26</i>			
↓ /SK/	10.	<i>SUNG HW et al., "Mechanical properties of a porcine aortic valve fixed with a naturally occurring crosslinking agent", Biomaterials 1999; 20: 1759-1772</i>			

Examiner Signature	/Sharon Kennedy/	Date Considered	09/24/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Hsing-Wen Sung
Art Unit	
Examiner Name	

Attorney Docket Number

S&T- 134

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SKI	11	SUNG HW et al., "In vitro surface characterization of a biological patch fixed with a naturally occurring crosslinking agent" <i>Biomaterials</i> 2000; 21: 1353-1362	
	12	TSAI CC et al., "In vitro evaluation of the genotoxicity of a naturally occurring crosslinking agent (genipin) for biologic tissue fixation" <i>J Biomed Mater Res</i> 2000; 52: 58-65	
	13	SUNG HW et al., "Fixation of biological tissues with a naturally occurring crosslinking agent: Fixation rate and effects of pH, temperature, and initial fixative concentration" <i>J Biomed Mater Res</i> 2000; 52: 77-87	
	14	SUNG HW et al., "Extraction of a naturally occurring crosslinking agent (genipin) from Gardenia fruits and its applications in biological tissue fixation" in <i>Biomaterials and Drug Delivery toward New Millennium</i> , edited by Park KD et al., " pages 623-632 (2000), published by Han Rin Won Publishing Co.	
	15	TSAI CC et al., "Effects of heparin immobilization on the surface characteristics of a biological tissue fixed with a naturally occurring crosslinking agent" <i>Biomaterials</i> 2001; 22: 523-533	
	16	SUNG HW et al., "stability of a biological tissue fixed with a naturally occurring crosslinking agent (genipin)" <i>J Biomed Mater Res</i> 2001; 55: 538-546	
	17	CHANG Y et al., "Reconstruction of the right ventricular outflow tract with a bovine jugular vein graft fixed with a naturally occurring crosslinking agent (genipin) in a canine model" <i>J Thorac Cardiovasc Surg</i> 2001; 122: 1208-1218	
↓ /SKI	18	MI FL et al., "In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant" <i>Biomaterials</i> 2002; 23: 181-191	

Examiner Signature	/Sharon Kennedy/	Date Considered	09/24/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
				Application Number	
				Filing Date	
				First Named Inventor	Hsing-Wen Sung
				Art Unit	
				Examiner Name	
Sheet	5	of	5	Attorney Docket Number	S&T-134

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/SKI/	19	MI FL et al., "Drug release from chitosan-alginate complex beads reinforced by a naturally occurring cross-linking agent" <i>Carbohydrate Polymers</i> 2002; 48: 61-72				
	20	CHANG Y et al., "In vivo evaluation of cellular and acellular bovine pericardia fixed with a naturally occurring crosslinking agent (genipin)" <i>Biomaterials</i> 2002; 23: 2447-2457				
	21	LIANG HC et al., "Genipin-crosslinked gelatin microspheres as a drug carrier for intramuscular administration - in vitro and in vivo studies" <i>J Biomed Mater Res</i> 2003; 65A: 271-282				
	22	Biocompatibles "PC technology overview" 2004				
	23	News Release "TCT: ABT-578-eluting stent demonstrates robust results" Washington DC, September 23, 2003				
	24	News Release "First human implant heralds next generation of coronary stent system" Santa Rose, CA, January 7, 2003				
↓ /SKI/	25	News Release "Endeavor I: IVUS analysis of ABT-578-eluting stent trial confirms early safety" New Orleans, LA, ACC 2004				

Examiner Signature	/Sharon Kennedy/	Date Considered	09/24/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.